Martindale Pharma has introduced a new addition to its Tapclob range – the UK’s first licensed oral liquid suspension of the anti-epileptic medicine clobazam.

Both strengths of Tapclob (5mg/5ml and 10mg/5ml) are now available in a 250ml bottle as well as the 150ml bottle. The larger size will benefit a significant number of patients with epilepsy by reducing the number of bottles they need. In addition, all packs will now include a 5ml oral syringe and a 30ml dosing cup, making it easier for patients and carers to measure doses accurately.

Michael Clark, Martindale Pharma chief marketing officer, said: “Tapclob is continuing to adapt to the needs of both prescribers and patients alike in a therapeutic area where ease of use is really important.”